Supplemental Material: Ofatumumab for the management of Refractory Pemphigus Vulgaris: A Case Series and Treatment Outcomes
Description
Supplementary Figure 1: Patient one; desmoglein-3 Antibody Titre (U/mL) and treatments received. Red indicates the period of SC monthly ofatumumab 20mg (clinical trial) and green indicates the period of IV monthly ofatumumab 20mg. Supplementary Figure 2: Patient one; Pemphigus vulgaris in oral mucosa. A) at baseline, B) 7 months post treatment with SC ofatumumab, C) At a recent follow up in 2024. Supplementary Figure 3: Patient two; desmoglein-3 Antibody Titre (U/mL) and treatments received. Red indicates the period of SC monthly ofatumumab 20mg (clinical trial) and green indicates the period of IV monthly ofatumumab 20mg. Supplementary Figure 4: Patient two; Pemphigus Vulgaris of oral mucosa. A) At baseline, B) Trial cessation – complete remission 6 months post ofatumumab initiation, C) Relapse of PV 4 months post ofatumumab cessation PDAI-TAS 4, D) In 2018 on IV ofatumumab 20mg monthly. Supplementary Figure 5: Patient three; desmoglein-3 antibody Index and treatments received. Red indicates the period of compassionate SC weekly ofatumumab 20mg and green indicates the period of compassionate intralesional ofatumumab 20mg.